Alterity Therapeutics Limited (PRNAF)

Market Cap	20.56M
Revenue (ttm)	2.68M
Net Income (ttm)	-12.76M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	0.0036
Previous Close	0.0068
Day's Range	0.0036 - 0.0036
52-Week Range	0.0002 - 0.0068
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 27, 2025

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: PRNAF

Financial Performance

In 2024, Alterity Therapeutics's revenue was 4.02 million, an increase of 2.63% compared to the previous year's 3.92 million. Losses were -19.12 million, 38.5% more than in 2023.

Financial numbers in AUD